| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DYNC2LI1 |
| Uniprot No | Q8TCX1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-352aa |
| 氨基酸序列 | MPSETLWEIAKAEVEKRGINGSEGDGAEIAEKFVFFIGSKNGGKTTIILRCLDRDEPPKPTLALEYTYGRRAKGHNTPKDIAHFWELGGGTSLLDLISIPITGDTLRTFSLVLVLDLSKPNDLWPTMENLLQATKSHVDKVIMKLGKTNAKAVSEMRQKIWNNMPKDHPQDHELIDPFPVPLVIIGSKYDVFQDFESEKRKVICKTLRFVAHYYGASLMFTSKSEALLLKIRGVINQLAFGIDKSKSICVDQNKPLFITAGLDSFGQIGSPPVPENDIGKLHAHSPMELWKKVYEKLFPPKSINTLKDIKDPARDPQYAENEVDEMRIQKDLELEQYKRSSSKSWKQIELDS |
| 预测分子量 | 44.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DYNC2LI1重组蛋白的3篇代表性文献概览(注：文献为虚构示例，实际研究中请通过学术数据库验证)：
1. **标题**：*"DYNC2LI1重组蛋白的克隆表达及其在纤毛运输中的功能研究"*
**作者**：Smith H, et al.
**摘要**：研究通过大肠杆菌系统表达并纯化DYNC2LI1重组蛋白，发现其与动力蛋白复合体DYNCI的结合能力，并证实其在纤毛内运输中调控货物蛋白的定位，突变体实验揭示了与短肋胸廓发育不良症的关联。
2. **标题**：*"DYNC2LI1突变对动力蛋白复合体组装的影响：基于重组蛋白的体外重建实验"*
**作者**：Doe J, et al.
**摘要**：利用昆虫细胞系统表达DYNC2LI1重组蛋白及突变体，通过体外复合体组装实验证明，其C端结构域对动力蛋白二聚化至关重要，致病性突变导致复合体稳定性下降，影响细胞内运输功能。
3. **标题**：*"DYNC2LI1重组蛋白的结构解析及其与LIC3的功能互作"*
**作者**：Lee R, et al.
**摘要**：通过冷冻电镜技术解析DYNC2LI1重组蛋白的三维结构，揭示其与动力蛋白轻链LIC3的互作界面，并提出该互作在调控鞭毛组装中的分子机制，为相关纤毛病的药物设计提供结构基础。
**提示**：实际研究中，建议在PubMed或Google Scholar中以“DYNC2LI1 recombinant protein”“DYNC2LI1 expression”等关键词检索，并筛选涉及蛋白表达纯化、功能验证或结构研究的文献。
DYNC2LI1 (Dynein Cytoplasmic 2 Light Intermediate Chain 1) is a critical component of the cytoplasmic dynein-2 complex, a motor protein responsible for retrograde intraflagellar transport (IFT) in ciliated cells. This protein plays a pivotal role in maintaining cilium structure and function by regulating the movement of cargo along microtubules from the ciliary tip toward the cell body. Dysfunction in DYNC2LI1 is linked to ciliopathies, such as short-rib thoracic dysplasia (SRTD), a genetic disorder characterized by skeletal abnormalities and impaired organ development due to defective ciliary signaling.
Recombinant DYNC2LI1 proteins are engineered in vitro using expression systems like *E. coli* or mammalian cells, enabling researchers to study its biochemical properties, interactions with dynein subunits (e.g., DYNC2H1), and mechanisms underlying ciliary transport. These proteins are essential for structural analyses (e.g., X-ray crystallography or cryo-EM) to map binding domains and post-translational modification sites. Additionally, recombinant DYNC2LI1 serves as a tool for functional assays, including ATPase activity measurements or in vitro reconstitution of IFT complexes, aiding in the identification of pathogenic mutations. Its applications extend to drug screening platforms aimed at rescuing ciliary defects in disease models. By providing a pure, scalable source of DYNC2LI1. recombinant technology accelerates both basic research and therapeutic development for ciliopathies.
×
